Agilent Technologies, Inc. $A Stock: Curated Wealth Partners LLC Trims Stake

Curated Wealth Partners LLC lessened its stake in shares of Agilent Technologies, Inc. (NYSE:A) by 98.5% in the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 4,134 shares of the medical research company’s stock after selling 278,810 shares during the period. Curated Wealth Partners LLC’s holdings in Agilent Technologies were worth $712,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the stock. WealthPlan Investment Management LLC bought a new position in Agilent Technologies in the 3rd quarter worth approximately $245,000. Mather Group LLC. raised its position in shares of Agilent Technologies by 8.0% in the third quarter. Mather Group LLC. now owns 2,907 shares of the medical research company’s stock worth $501,000 after buying an additional 215 shares in the last quarter. Godsey & Gibb Inc. grew its position in Agilent Technologies by 1.5% during the third quarter. Godsey & Gibb Inc. now owns 178,388 shares of the medical research company’s stock worth $30,738,000 after buying an additional 2,660 shares in the last quarter. Generate Investment Management Ltd boosted its position in shares of Agilent Technologies by 10.8% during the 3rd quarter. Generate Investment Management Ltd now owns 89,766 shares of the medical research company’s stock valued at $15,468,000 after acquiring an additional 8,720 shares during the last quarter. Finally, First Citizens Bank & Trust Co. purchased a new position in shares of Agilent Technologies during the third quarter worth about $1,080,000.

Agilent Technologies Stock Up 0.9%

Shares of A opened at $175.54 on Friday. The company has a current ratio of 2.05, a quick ratio of 1.56 and a debt-to-equity ratio of 0.50. The business’s 50 day moving average is $158.46 and its 200 day moving average is $137.30. Agilent Technologies, Inc. has a 12-month low of $108.35 and a 12-month high of $177.05. The company has a market capitalization of $49.49 billion, a PE ratio of 34.56, a price-to-earnings-growth ratio of 2.65 and a beta of 1.21.

Agilent Technologies (NYSE:A) last issued its quarterly earnings data on Wednesday, August 26th. The medical research company reported $1.62 earnings per share for the quarter, beating analysts’ consensus estimates of $1.49 by $0.13. Agilent Technologies had a return on equity of 24.45% and a net margin of 19.53%. The firm had revenue of $1.88 billion during the quarter, compared to analyst estimates of $1.84 billion. During the same quarter last year, the business posted $1.37 earnings per share. The business’s quarterly revenue was up 8.1% compared to the same quarter last year. Agilent Technologies has set its Q4 2026 guidance at 1.710-1.740 EPS and its FY 2026 guidance at 6.180-6.210 EPS. Research analysts expect that Agilent Technologies, Inc. will post 6.20 earnings per share for the current fiscal year.

Agilent Technologies Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 28th. Stockholders of record on Tuesday, October 6th will be issued a $0.2550 dividend. The ex-dividend date is Tuesday, October 6th. This represents a $1.02 dividend on an annualized basis and a dividend yield of 0.6%. Agilent Technologies’s payout ratio is 20.08%.

Analysts Set New Price Targets

A number of analysts recently weighed in on the company. Citigroup boosted their target price on Agilent Technologies from $185.00 to $190.00 and gave the stock a “buy” rating in a research report on Thursday, August 27th. UBS Group began coverage on Agilent Technologies in a research report on Wednesday, September 9th. They set a “neutral” rating and a $165.00 price target for the company. Morgan Stanley raised their target price on shares of Agilent Technologies from $175.00 to $190.00 and gave the stock an “overweight” rating in a research report on Tuesday. TD Cowen raised their price objective on Agilent Technologies from $180.00 to $196.00 and gave the company a “buy” rating in a research report on Tuesday. Finally, The Goldman Sachs Group raised their price objective on Agilent Technologies from $155.00 to $175.00 and gave the company a “buy” rating in a research report on Thursday, August 27th. Fifteen equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $173.65.

Agilent Technologies News Summary

Here are the key news stories impacting Agilent Technologies this week:

• Positive Sentiment: Analyst price-target support: Morgan Stanley forecast meaningful appreciation for Agilent shares, while TD Cowen raised its price target. The revisions reinforce positive Wall Street sentiment and suggest analysts see additional upside despite the stock’s recent gains. Morgan Stanley Forecasts Strong Price Appreciation for Agilent Technologies Stock Agilent Technologies Stock Gets Price Target Bump from TD Cowen
• Positive Sentiment: Proscia acquisition expands AI capabilities: Agilent agreed to acquire pathology-software company Proscia for $240 million upfront, with the total consideration potentially reaching $270 million through milestones. The deal would strengthen Agilent’s position in AI-enabled digital pathology and scientific intelligence, adding a potentially faster-growing software component to its tools and diagnostics portfolio. Agilent Technologies to Acquire Proscia
• Positive Sentiment: Favorable market backdrop: A new industry report projects the global metabolomics market will expand at a 17.3% compound annual growth rate through 2030. Agilent is identified as one of the companies positioned to benefit as laboratories adopt AI-assisted diagnostics and advanced analytical technologies. Global Metabolomics Market Report 2026
• Neutral Sentiment: China expansion: Agilent plans to expand its capabilities in China, which could improve access to regional demand and support longer-term growth. However, execution, regulatory and geopolitical risks remain considerations for investors. Agilent to Expand Capabilities in China
• Negative Sentiment: Acquisition costs and integration risk: The Proscia transaction requires substantial capital and may create integration and milestone-payment risks before it contributes materially to earnings. With Agilent already trading at a premium valuation, investors may scrutinize the deal’s execution and return on investment.

Insider Buying and Selling

In other news, Director Mikael Dolsten sold 634 shares of the stock in a transaction on Friday, September 4th. The shares were sold at an average price of $151.38, for a total value of $95,974.92. Following the sale, the director owned 4,924 shares of the company’s stock, valued at approximately $745,395.12. This represents a 11.41% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

About Agilent Technologies

Agilent Technologies, Inc is an analytical measurement and laboratory technology company serving the life sciences, diagnostics, pharmaceutical, chemical, environmental, food, energy and academic research markets. Its solutions help laboratories analyze the composition, quality and performance of materials, biological samples and other substances.

The company’s products and services include liquid and gas chromatography systems, mass spectrometry instruments, spectroscopy equipment, laboratory automation tools, software, consumables and supplies.